https://doi.org/10.4081/hmr.v1i8.282

Palifermin (Kepivance™) in the treatment of mucositis

Vol. 1 No. 8: New Drugs in Hematology, Bologna, October 9-11, 2005
Published: May 29, 2009
Abstract Views: 176
PDF: 340
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Christer Emmanouilides
support@pagepress.org
In patients undergoing high dose chemotherapy and hematopoietic stem cell transplant, oral mucositis (OM) is one of the most debilitating and annoying side effects. This complication results from cytotoxic injury to the epithelial lining of the oropharyngeal mucosa, although lesions of the whole gastrointestinal tract also occur.1 The severity of OM varies from erythema and edema accompanied by mild soreness to full mucosal thickness ulcerations penetrating into the submucosa, often resulting in severe pain requiring narcotic analgesia and impaired swallowing, prolonged hospitalization, and increased risks for infections and potentially life-threatening sequelae.2,3 Between 40% to 80% of cancer patients undergoing intensive treatment regimens requiring hematopoietic stem cell transplantation (HSCT) suffer the debilitating effects of OM during their cancer therapy.4,7

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Emmanouilides, C. (2009). Palifermin (Kepivance™) in the treatment of mucositis. Hematology Meeting Reports (formerly Haematologica Reports), 1(8). https://doi.org/10.4081/hmr.v1i8.282
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).